Shares of Dexcom fell 9% in extended trading on Thursday after the company released third-quarter results that beat analysts' expectations but showed a decline in U.S. revenue year over year.Here's how the company did:Earnings per share: 45 cents adjusted vs. 43 cents expected by LSEGRevenue:  $994 million vs. $990 million expected by LSEGThe company's revenue increased 2% to $994.2 million from $975 million a year earlier. Dexcom's U.S. revenue declined 2% from $713.6 million the prior year. The company re ...

财务业绩 - 2024年第三季度收入同比增长2%至9.942亿美元，其中美国收入下降2%，国际收入增长12%[2] - 2024年第三季度GAAP营业利润为1.52亿美元，占收入的15.3%，同比下降580个基点；非GAAP营业利润为2.12亿美元，占收入的21.3%，同比下降320个基点[5] - 2024年全年预计收入约40-40.5亿美元，同比增长11-13%[3] - 2024年全年预计非GAAP毛利率约63%，非GAAP营业利润率约20%，调整后EBITDA利润率约29%[3] - 第三季度收入为9.942亿美元，同比增长2%[13] - 第三季度国内收入为7.019亿美元，同比下降2%[14] - 第三季度国际收入为2.923亿美元，同比增长12%[14] - 第三季度传感器及其他收入为9.518亿美元，同比增长9%[15] - 第三季度硬件收入为4,240万美元，同比下降58%[15] - 第三季度非GAAP毛利为6.259亿美元，非GAAP毛利率为63%[16] - 第三季度非GAAP营业利润为2.12亿美元，非GAAP营业利润率为21.3%[16] - 第三季度非GAAP净利润为1.799亿美元，非GAAP净利润率为18.1%[16] - 第三季度调整后EBITDA为3.001亿美元[16] - 前三季度收入为29.195亿美元，同比增长13%[13] - 公司报告了三个月和九个月期间的GAAP净收入分别为1.346亿美元和4.245亿美元[17] - 公司报告了三个月和九个月期间的非GAAP净收入分别为1.799亿美元和4.824亿美元[17] - 公司报告了三个月和九个月期间的GAAP稀释每股收益分别为0.34美元和1.04美元[17] - 公司报告了三个月和九个月期间的非GAAP稀释每股收益分别为0.45美元和1.19美元[17] - 公司报告了三个月和九个月期间的GAAP稀释加权平均股数分别为410.2百万股和414.7百万股[17] - 公司报告了三个月和九个月期间的非GAAP稀释加权平均股数分别为402.5百万股和407.0百万股[17] 产品发布与市场拓展 - 推出面向2型糖尿病和糖尿病前期患者的新产品Stelo，这是美国首款非处方用途的葡萄糖生物传感器[2] - 在澳大利亚和法国推出Dexcom G7和Dexcom ONE+产品[2] - 提交Dexcom G7 15天CGM系统至FDA审批[2] 其他重大事项 - 执行了7.5亿美元的股票回购计划[2] - 执行副总裁兼首席商务官Teri Lawver将于年底退休，由CEO Kevin Sayer临时接管商务部门[4] - 公司剔除了与专利诉讼、业务过渡和其他重大事项相关的费用[17,19,20,21,22,23] - 公司剔除了与股权投资相关的收益或损失[17,23] - 公司剔除了与税务相关的调整[17,23] - 公司提供了非GAAP财务指标以更好地反映公司的经营业绩[19,20,21,22,23]

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on behalf of long-term stockholders following a class action complaint that was filed against DexCom on August 21, 2024 with a Class Period from April 28, 2023 to July 25, 2024. Our investigation concerns whether the board of directors of DexCom have breached their fiduciary duties to the company. According to the ...

DexCom, Inc. (DXCM) is scheduled to release third-quarter 2024 results on Oct. 24, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 10.26%.The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 23.03%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $991.6 million, indicating growth of 1.7% from ...

In its upcoming report, DexCom (DXCM) is predicted by Wall Street analysts to post quarterly earnings of $0.43 per share, reflecting a decline of 14% compared to the same period last year. Revenues are forecasted to be $991.55 million, representing a year-over-year increase of 1.7%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

文章核心观点 - 根据诉讼,在2024年1月8日至2024年7月25日期间(包括这两个日期),DexCom公司向投资者发布了虚假和误导性的信息,隐瞒了公司销售团队无法执行公司预期增长潜力的事实[1][3] - 当真实情况被披露时,投资者遭受了损失[3] 公司概况 - DexCom公司是一家医疗设备公司,主要从事糖尿病连续血糖监测系统的研发和销售[1] - 公司股票代码为NASDAQ: DXCM[1] 诉讼情况 - 罗森律师事务所代表投资者对DexCom公司提起集体诉讼[1][2] - 投资者如果在上述时间段内购买了DexCom公司的证券,可能有资格获得赔偿,无需支付任何费用[1] - 投资者需要在2024年10月21日之前申请成为首席原告,代表其他集体成员参与诉讼[1] - 罗森律师事务所在证券集体诉讼方面拥有丰富的经验和成功案例,是一家值得信赖的律所[2]

RADNOR, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONTA ...

Recent developments might have scared away some investors, but patience could pay off.Over the past five years, diabetes-focused medical device specialist DexCom (DXCM -0.50%) has made meaningful progress on several fronts. The company launched new products in the continuous glucose monitoring (CGM) niche and entered new geographies. Its revenue has generally increased at a good pace on a year-over-year basis.However, after a recent plunge, DexCom has underperformed the S&P 500 in the past half-decade. Can ...

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the DexCom class action lawsuit – captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.) – charges DexCom, Inc. (NASDAQ: DXCM) and certain of DexCom’s top executives with violations of the Securities Exchange Act of 1934. Subsequently filed complaints are captioned Oakland County Employees’ Retirement System v. DexCom, Inc., No. 24-cv-01804 (S.D. Cal.), and Carnes v. DexCom, Inc., No. 24-cv-01809 (S.D. Cal.). ...